RxDoctor Payments Data

Hope Sims, APRN

Family · Gainesville, FLNPI 1639868664

Payments from drug & device makers

$941in general payments, 2019–2025

Across 17 payments — averaging $55.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$170
  • Pharming Healthcare, Inc.$130
  • AbbVie$123
  • AstraZeneca$119
  • Regeneron Healthcare Solutions, Inc.$109
  • Alnylam Pharmaceuticals Inc.$78
  • plus $212 from 6 others

What the payments were for

  • Food & beverage$941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$547
Medicare patients
11
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$37,728
EliquisApixaban27$22,864
OzempicSemaglutide11$18,418
TrulicityDulaglutide11$14,192
ShingrixVaricella-Zoster Ge/As01b/Pf44$6,889
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,912
Gabapentin76$1,137
Albuterol Sulfate HfaAlbuterol Sulfate39$911
Ventolin HfaAlbuterol Sulfate13$721
Atorvastatin Calcium102$710
Omeprazole32$558
Metoprolol Succinate28$503
Losartan Potassium57$409
Duloxetine Hcl17$400
Levothyroxine Sodium41$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$38$14,19211 claims
GSKShingrix$170$6,88944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →